alexa Nanomedicines: Future Against Infections | OMICS International
ISSN: 2150-3494
Chemical Sciences Journal
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Nanomedicines: Future Against Infections

Narayanasamy P*

Department of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA

*Corresponding Author:
Narayanasamy P
UNMC Department of Pathology and
Microbiology985900 Nebraska Medical Center
Omaha, USA
Tel: 402-559-9120
Fax: 402-559-6018
E-mail: [email protected]

Received date: September 22, 2014; Accepted date: September 24, 2014; Published date: September 30, 2014

Citation: Narayanasamy P (2014) Nanomedicines: Future Against Infections. Chem Sci J 5:e105. doi: 10.4172/2150-3494.1000e105

Copyright: © 2014 Narayanasamy P. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Chemical Sciences Journal

The World Health Organization estimates that around 1.5 billion people are currently infected with latent Mycobacterial tuberculosis (MTB). However, each year, 8 million people develop active disease and 3 million die. Approximately 20% of these cases are multiple drug resistant (MDR-TB), resistant to the main first-line drugs isoniazid and rifampin, and 2% are extensively drug resistant (XDR-TB), resistant to isoniazid, rifampin, fluoroquinolones and at least one of three secondline drugs (amikacin, kanamycin, or capreomycin). Despite, no new classes of anti-TB drugs or drug formulations have been introduced clinically since the 1980’s [1].

Over and above Human Immunodeficiency Virus (HIV) is a global infectious disease causing significant morbidities and mortality within an infected human host. These all have contributed to an alarming millions of infected people worldwide [2]. Further complicating disease outcomes are combined HIV and MTB co-infections. In addition the frequent occurrence of HIV-MTB co-infection can favor development of MDR-TB and XDR-TB. Thus, improvements in drug access and simplified treatment regimens are needed immediately. In this context, the design and development of long-acting formulations of traditional anti-MTB and anti-HIV drugs is of great interest [3]. We posit that one way this can be achieved is through nanoformulated drugs [4].

Conjointly, Gram-negative bacteria are common causes of Intra- Abdominal Infections (IAIs), Urinary Tract Infections (UTIs), nosocomial pneumonia, and bacteremia. Escherichia coli (E.coli) and Pseudomonas aeruginosa (P. aeruginosa) are important pathogens in the hospital setting, accounting for 27% of all pathogens and 50% of all Gram-negative pathogens causing healthcare-associated. Gramnegative bacteria are resistant to multiple drugs and are increasingly resistant to most available antibiotics. These bacteria have built-in abilities to find new ways to be resistant and can pass along genetic materials that allow other bacteria to become drug-resistant as well. Antibiotic-resistant infections pose considerable challenges to clinicians in relation to diagnosis, treatment, and infection control, as well as considerable costs. The estimates of the healthcare costs to the world economy for antibiotic-resistant infections have risen as high as $40 billion. Treatment options to meet this challenge are increasingly limited. There is a critical need for new antibiotics and techniques to meet the needs of patients now and in the future.

Generally treatment of bacterial or viral disease requires long time and daily prescription in addition to drug resistance. For example tuberculosis treatment has to be continued for minimum 6-12 months’ time period and HIV treatment should be carried out for years. In that regard development of non-resistant and long acting drugs are increasingly in need.

Loading antibiotics in nanoparticles will restore their ability to destroy bacteria including that have acquired resistance to them. Furthermore, nanoparticles loaded with antibiotics have been shown to increase the concentration of antibiotics at the site of bacterium– antibiotic interaction in sub-cellular level, and it facilitatesthe binding of antibiotics to bacteria in the process of killing the bacteria [4]. Nanoparticles also can have sustained drug release property for a certain time period depending on its property [4]. The sustained drug releasing nanoparticle can reduce the number of drug intake e.g. drug can be taken once in a week or two weeks. Nanomedicines also shows importance in treating neurodegenerative disorders because of its ability to pass through blood brain barrier [5]. Most importantly, such drug formulations have unquestioned translational potential.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11957
  • [From(publication date):
    December-2014 - Dec 11, 2017]
  • Breakdown by view type
  • HTML page views : 8097
  • PDF downloads : 3860
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

clini[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version